MGCD265 is an oral, multi-targeted, receptor tyrosine kinase inhibitor that targets MET, AXL, and PDGFR and is in clinical trials for non-small cell lung cancer (NSCLC), head and neck cancers, and advanced malignancies. Here, NTRK1 is linked to head and neck cancer.